WebSep 30, 2024 · PURPOSE The CheckMate 066 trial investigated nivolumab monotherapy as first-line treatment for patients with previously untreated BRAF wild-type advanced melanoma. Five-year results are presented herein. PATIENTS AND METHODS In this multicenter, double-blind, phase III study, 418 patients with previously untreated, … WebOct 12, 2024 · Here, we report CheckMate 227 Part 1 efficacy and safety data with a minimum follow-up of 5 years, the longest report from a phase III trial with an immunotherapy combination for NSCLC and an important survival landmark for …
Long-Term Data Show Nivolumab May Provide Sustained Benefit …
WebNov 7, 2024 · Hammers HJ, Motzer RJ, Tannir NM, et al. Conditional survival and 5-year follow-up in CheckMate 214: first-line nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) in advanced renal cell ... ilovepdf pdf a html
Checkmate - Rotten Tomatoes
WebSep 28, 2024 · Jeffrey S. Weber of the Perlmutter Cancer Centre, NYU Langone Medical Centre in New York, USA presented updated results with 36 months of follow-up from the CheckMate 238 trial. Previously reported findings showed that the efficacy benefit demonstrated with nivolumab compared with ipilimumab was sustained at 24 months. WebMay 28, 2024 · 9506 Background: In the phase 3 CheckMate 067 trial, a durable and sustained clinical benefit was achieved with nivolumab (NIVO) + ipilimumab (IPI) and NIVO alone vs IPI at 5-y of follow-up (overall survival [OS] and progression-free survival [PFS] rates: 52%, 44%, 26% and 36%, 29%, 8%, respectively). Here we report 6.5-y efficacy … WebCheckMate-238 included 906 patients with completely resected stage IIIB-IIIC or IV melanoma. Patients were randomized into equal groups to treatment with either nivolumab (3 mg/kg every 2 weeks and every 12 weeks thereafter) or ipilimumab (10 mg/kg every 3 weeks for 4 doses and every 12 weeks thereafter) for a maximum of 1 year or until … ilovepdf pdf a word juntar